Forum Update: Supporting Community-Led Discussion
The forum was created as a space for shared learning and peer support, and as the community grows, we want to lean more fully into that purpose.
Going forward, PAAB will be taking a more listening-first role in forum discussions. Rather than responding immediately to every question, we’ll be encouraging members to engage with one another, share experiences, and help build collective understanding. PAAB will continue to monitor conversations and will step in to:
- Correct any misunderstandings
- Provide guidance when questions remain unanswered after a few days
- Support discussions where official clarification is needed
Our goal is to foster a collaborative, trusted community where knowledge is shared and strengthened by everyone’s contributions.
Thank you for being part of the conversation.
114 - Does PAAB have any oversight on companies that advertise a system for treating periodontal disease through use of non-proprietary antibiotics among other diagnostic and treatment protocols?
-
We would need more information to answer this. The answer would depend on the following: What is the Federal category of the Terms of Marketing Authorization (TMA) for the medications? Is the promotional material directed to health care professionals (HCPs)? Is the "system" approved by Health Canada as a device? If the promotional material is directed to HCPs, the PAAB reviews the content irrespective of the medication's Federal schedule (i.e. whether the product is a prescription, non-prescription, or a natural health product). If the material is directed to consumers in the waiting room, the PAAB would review the messaging for prescription drugs and schedule D drugs. The PAAB would not review claims about the device itself if "the system" had been approved by Health Canada as a medical device. Please call the PAAB office if you have any questions or require further information for your specific case.
